Table 3.
The demographic data of all patients with major depressive disorder and respective COMT Val158Met genotypes
| All patients (N=45) | Val/Val (N=19) | Met carrier (N=26) | P-value | |
|---|---|---|---|---|
| Age (years) | 50.6±15.3 | 48.6±15.7 | 52.1±15.1 | 0.455* |
| Sex (male/female) (n) | 23/22 | 10/9 | 13/13 | 0.861** |
| DLX max dose (mg/day) | 49.3±12.3 | 50.0±12.9 | 48.9±12.1 | 0.760* |
| Depressive episodes before DLX treatment | 1.09±1.70 | 0.68±1.25 | 1.39±1.94 | 0.176* |
| Baseline HAMD17 | 21.2±4.9 | 21.9±5.5 | 20.7±4.4 | 0.437* |
| After 8 weeks HAMD17 score | 9.0±5.4 | 8.3±4.4 | 9.5±6.1 | 0.489* |
| Delta HAMD17 score (0w–8w) | 12.2±6.1 | 13.6±6.2 | 11.3±5.9 | 0.212* |
| Response rate (%) | 66.7 | 68.4 | 65.4 | 0.831** |
Notes: P-values calculated using
*
Student’s t-test,
**
χ2 test. Data are presented as mean ± standard deviation unless otherwise stated.
Abbreviations: DLX, duloxetine; HAMD17, 17-item Hamilton Rating Scale for Depression; COMT, catechol-O-methyltransferase; Val, valine; Met, methionine; w, weeks.